Merck & Co., Inc. Derivative Liability, Fair Value, Gross Liability
Merck & Co., Inc. (MRK) had Derivative Liability, Fair Value, Gross Liability of $252.00 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Offsetting › Derivative Liability, Subject to Master Netting Arrangement, after Offset and Deduction › Derivative Liability, Subject to Master Netting Arrangement, after Offset
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2026-08-07
- 2026-06-30: Derivative Liability, Fair Value, Gross Liability $252.00M.
- 2026-03-31: Derivative Liability, Fair Value, Gross Liability $229.00M.
- 2025-12-31: Derivative Liability, Fair Value, Gross Liability $324.00M.
- 2025-09-30: Derivative Liability, Fair Value, Gross Liability $492.00M.
| Period end | Derivative Liability, Fair Value, Gross Liability |
|---|---|
| 2026-06-30 | $252.00M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $229.00M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $324.00M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $492.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $855.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $268.00M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $345.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $298.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $142.00M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $167.00M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $239.00M 10-K · filed 2025-02-25 |
| 2023-09-30 | $176.00M 10-Q · filed 2023-11-03 |
| 2022-12-31 | $409.00M 10-K · filed 2024-02-26 |
| 2015-06-30 | $145.00M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $115.00M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $103.00M 10-Q · filed 2015-08-06 |
| 2014-09-30 | $94.00M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $87.00M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $106.00M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $184.00M 10-K · filed 2015-02-27 |
| 2013-09-30 | $119.00M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $98.00M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $145.00M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $229.00M 10-K · filed 2014-02-27 |
| 2012-09-30 | $180.00M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $48.00M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $218.00M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $108.00M 10-K · filed 2013-02-28 |
| 2011-09-30 | $144.00M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $68.00M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $61.00M 10-K · filed 2012-02-28 |
| 2010-09-30 | $114.30M 10-Q · filed 2010-11-08 |
| 2010-06-30 | $71.80M 10-Q · filed 2010-08-06 |
| 2009-12-31 | $72.60M 10-Q · filed 2010-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |